

# Maarten J Van Der Doelen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1798738/publications.pdf>

Version: 2024-02-01

97  
papers

5,764  
citations

331670

21  
h-index

76900

74  
g-index

98  
all docs

98  
docs citations

98  
times ranked

8032  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 142-150.	3.9	5
2	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	3.9	19
3	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	1.9	3
4	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.. <i>Journal of Clinical Oncology</i> , 2022, 40, 516-516.	1.6	0
5	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. <i>Journal of Clinical Oncology</i> , 2022, 40, 40-40.	1.6	0
6	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	1.6	0
7	Immunological responses to adjuvant vaccination with combined CD1c <sup>+</sup> myeloid and plasmacytoid dendritic cells in stage III melanoma patients. <i>Oncolmmunology</i> , 2022, 11, .	4.6	14
8	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	6.4	5
9	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	2
10	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3
11	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	5.4	6
12	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	3.1	1
13	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	5.1	28
14	Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer". <i>European Journal of Cancer</i> , 2021, 144, 395-396.	2.8	0
15	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	3.9	8
16	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3325-3334.	6.4	15
17	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53
18	Baseline effector cells predict response and NKT cells predict pulmonary toxicity in advanced breast cancer patients treated with everolimus and exemestane. <i>International Immunopharmacology</i> , 2021, 93, 107404.	3.8	2

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5042-5042.	1.6	4
20	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
21	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 667658.	2.8	6
22	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. <i>Cancers</i> , 2021, 13, 2249.	3.7	28
23	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. <i>Journal of Palliative Medicine</i> , 2021, 24, 1789-1797.	1.1	4
24	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
25	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	1.6	34
26	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	1.6	13
27	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
28	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 802877.	4.8	5
29	Results of the York Mason Procedure with and without Concomitant Graciloplasty to Treat Iatrogenic Rectourethral Fistulas. <i>European Urology Focus</i> , 2020, 6, 762-769.	3.1	4
30	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	1.9	4
31	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
32	Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors. <i>European Urology</i> , 2020, 78, 822-830.	1.9	99
33	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	2.6	32
34	Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. <i>Future Oncology</i> , 2020, 16, 1371-1384.	2.4	25
35	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	3.0	18
36	A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2067-2075.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>OncImmunity</i> , 2020, 9, 1738814.	4.6	13
38	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	2.8	41
39	Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 477-488.	4.2	42
40	KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5543-5543.	1.6	17
41	Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane. <i>Targeted Oncology</i> , 2019, 14, 441-451.	3.6	11
42	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. , 2019, 7, 302.		72
43	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	1.9	5
44	Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3945-3952.	1.5	24
45	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy. <i>Clinical and Translational Oncology</i> , 2019, 21, 774-780.	2.4	7
46	Survival of the artificial urinary sphincter in a changing patient profile. <i>World Journal of Urology</i> , 2019, 37, 899-906.	2.2	2
47	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 79-87.	1.9	18
48	Does a food intervention makes abiraterone treatment affordable?. <i>Journal of Clinical Oncology</i> , 2019, 37, e16523-e16523.	1.6	0
49	The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study. <i>Targeted Oncology</i> , 2018, 13, 363-370.	3.6	4
50	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1064-1067.	2.4	7
51	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. <i>European Journal of Cancer</i> , 2018, 90, 1-9.	2.8	20
52	Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2018, 4, 694-701.	3.1	43
53	223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018, 43, 9-16.	1.3	18
54	Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2018, 55, e6-e8.	1.2	7

#	ARTICLE	IF	CITATIONS
55	68Ga-PSMA Uptake in Angiolipoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 757-758.	1.3	16
56	Everolimus Exposure and Early Metabolic Response as Predictors of Treatment Outcomes in Breast Cancer Patients Treated with Everolimus and Exemestane. <i>Targeted Oncology</i> , 2018, 13, 641-648.	3.6	10
57	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	4.8	107
58	Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4521-4521.	1.6	6
59	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5006-5006.	1.6	10
60	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	1.6	2
61	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 219-219.	1.6	2
62	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	1.6	5
63	Everolimus exposure and early metabolic response as predictors for treatment outcomes in breast cancer patients treated with everolimus and exemestane.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1062-1062.	1.6	0
64	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , 2017, 31, e3986.	1.7	20
65	Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients. <i>Scientific Reports</i> , 2017, 7, 43486.	3.3	16
66	Decline in artificial urinary sphincter survival in modern practice—do we treat a different patient?. <i>Neurourology and Urodynamics</i> , 2017, 36, 1350-1355.	1.5	3
67	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4530-4530.	1.6	6
68	Association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5525-5525.	1.6	6
69	A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 166-166.	1.6	2
70	Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 282-282.	1.6	6
71	Correlation between strength of T-cell response against HPV16 and survival after vaccination with HPV16 long peptides in combination with chemotherapy for late-stage cervical cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 140-140.	1.6	4
72	mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm. <i>International Journal of Cancer</i> , 2016, 138, 2312-2321.	5.1	76

#	ARTICLE	IF	CITATIONS
73	Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. <i>Drug Discovery Today</i> , 2016, 21, 962-976.	6.4	46
74	Charting Recent Progress and Challenges in Metastatic Castration-resistant Prostate Cancer: Is There an Optimal Treatment Sequence?. <i>European Urology Focus</i> , 2016, 2, 426-440.	3.1	3
75	Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. <i>Clinical Cancer Research</i> , 2016, 22, 1897-1906.	7.0	295
76	Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1369-1380.	3.5	74
77	Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. <i>Ophthalmology</i> , 2016, 123, 2265-2267.	5.2	44
78	Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. <i>Acta Oncologica</i> , 2016, 55, 1510-1512.	1.8	10
79	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1201625.	4.6	21
80	Dendritic cell vaccination in melanoma patients: From promising results to future perspectives. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2523-2528.	3.3	15
81	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolmmunology</i> , 2016, 5, e1105431.	4.6	11
82	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>Oncolmmunology</i> , 2016, 5, e1057673.	4.6	67
83	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	7.0	211
84	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 245-260.	1.6	45
85	Results of primary versus recurrent surgery to treat stress urinary incontinence in women. <i>International Urogynecology Journal</i> , 2015, 26, 997-1005.	1.4	8
86	Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS5070-TPS5070.	1.6	3
87	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	4.8	71
88	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	10.7	1,280
89	Results of subset analyses on overall survival (OS) from study CA184-043: Ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2-2.	1.6	11
90	Characterization of immune-related adverse events (irAEs) in a phase 3 trial of ipilimumab (Ipi) versus placebo (Pbo) in post-docetaxel mCRPC.. <i>Journal of Clinical Oncology</i> , 2014, 32, 52-52.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. Journal of Clinical Oncology, 2014, 32, 109-109.	1.6	0
92	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Journal of Clinical Oncology, 2014, 32, 242-242.	1.6	1
93	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	27.0	2,412
94	Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2013, 31, 5055-5055.	1.6	1
95	CA184-095: A randomized, double-blind, phase III trial to compare the efficacy of ipilimumab (Ipi) versus placebo in asymptomatic or minimally symptomatic patients (pts) with metastatic chemotherapy-naive castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, TPS5093-TPS5093.	1.6	4
96	Awareness and understanding of cancer immunotherapy in Europe.. Journal of Clinical Oncology, 2013, 31, 3053-3053.	1.6	0
97	A cohort compassionate-use program with cabazitaxel plus prednisone for patients with metastatic castration-resistant prostate cancer: Interim results.. Journal of Clinical Oncology, 2012, 30, 172-172.	1.6	1